Kanjin Therapeutics develops novel advanced therapeutics aimed at halting the progression of kidney disease and restoring kidney function, with the goal of eliminating the need for dialysis. Their approach focuses on creating disease‑modifying treatments that target the underlying causes of renal failure rather than merely managing symptoms. By pursuing curative solutions, Kanjin seeks to transform chronic kidney disease into a condition that can be effectively treated and potentially reversed.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic kidney disease often progresses to end-stage renal failure, requiring patients to undergo lifelong dialysis or kidney transplantation, which are costly, invasive, and limit quality of life.
Solution
Kanjin Therapeutics is developing advanced molecular therapeutics that intervene in the fundamental pathways of kidney injury to stop disease progression and promote regeneration of renal tissue. By targeting the underlying mechanisms of chronic kidney damage, their candidates aim to restore functional nephrons and eliminate the need for dialysis. Preclinical and early clinical programs focus on demonstrating safety, efficacy, and durable improvement in kidney function, offering a potential curative option for patients currently dependent on renal replacement therapy.
Target Audience
Primary customers are pharmaceutical partners, biotech investors, and clinical research organizations focused on nephrology, as well as healthcare systems seeking disease‑modifying treatments for patients with chronic kidney disease.
Features
- Novel small‑molecule and biologic agents designed to modulate key signaling pathways involved in renal fibrosis and inflammation
- Mechanism‑based approach that seeks to regenerate functional kidney tissue rather than provide symptomatic support
- Preclinical models showing reversal of established kidney injury and restoration of glomerular filtration rate
- Early-phase clinical trial designs incorporating biomarkers of kidney repair and functional endpoints
- Proprietary delivery platforms optimized for renal targeting and sustained therapeutic exposure